1. Home
  2. RYTM vs TRNO Comparison

RYTM vs TRNO Comparison

Compare RYTM & TRNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • TRNO
  • Stock Information
  • Founded
  • RYTM 2008
  • TRNO 2009
  • Country
  • RYTM United States
  • TRNO United States
  • Employees
  • RYTM N/A
  • TRNO N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • TRNO Real Estate
  • Sector
  • RYTM Health Care
  • TRNO Finance
  • Exchange
  • RYTM Nasdaq
  • TRNO Nasdaq
  • Market Cap
  • RYTM 6.4B
  • TRNO 6.0B
  • IPO Year
  • RYTM 2017
  • TRNO 2010
  • Fundamental
  • Price
  • RYTM $98.54
  • TRNO $61.39
  • Analyst Decision
  • RYTM Strong Buy
  • TRNO Buy
  • Analyst Count
  • RYTM 12
  • TRNO 10
  • Target Price
  • RYTM $117.00
  • TRNO $65.40
  • AVG Volume (30 Days)
  • RYTM 629.6K
  • TRNO 662.1K
  • Earning Date
  • RYTM 11-04-2025
  • TRNO 11-05-2025
  • Dividend Yield
  • RYTM N/A
  • TRNO 3.36%
  • EPS Growth
  • RYTM N/A
  • TRNO 75.67
  • EPS
  • RYTM N/A
  • TRNO 3.15
  • Revenue
  • RYTM $174,334,000.00
  • TRNO $442,611,000.00
  • Revenue This Year
  • RYTM $46.10
  • TRNO $21.54
  • Revenue Next Year
  • RYTM $63.02
  • TRNO $10.87
  • P/E Ratio
  • RYTM N/A
  • TRNO $19.66
  • Revenue Growth
  • RYTM 54.92
  • TRNO 21.13
  • 52 Week Low
  • RYTM $45.91
  • TRNO $48.18
  • 52 Week High
  • RYTM $116.00
  • TRNO $69.20
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 39.87
  • TRNO 60.79
  • Support Level
  • RYTM $95.27
  • TRNO $56.09
  • Resistance Level
  • RYTM $102.20
  • TRNO $62.87
  • Average True Range (ATR)
  • RYTM 4.86
  • TRNO 1.31
  • MACD
  • RYTM -1.75
  • TRNO 0.20
  • Stochastic Oscillator
  • RYTM 17.51
  • TRNO 78.60

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About TRNO Terreno Realty Corporation

Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.

Share on Social Networks: